Compare
ZyVersa Therapeutics, Inc. vs Regen BioPharma Inc vs ProtoKinetix, Inc. vs Bioxytran, Inc
| Latest fiscal year | ZyVersa Therapeutics, Inc. ZVSA | Regen BioPharma Inc RGBP | ProtoKinetix, Inc. PKTX | Bioxytran, Inc BIXT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $236.6K | n/a | n/a |
| Revenue growth (YoY) | n/a | 0.0% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -143.1% | n/a | n/a |
| Net margin | n/a | -538.8% | n/a | n/a |
| Net income | -$24.95M | -$1.27M | -$393.6K | -$2.12M |
| EPS (Diluted) | -$4.18 | -$0.05 | $0.00 | -$0.02 |
| Operating cash flow | -$5.11M | -$383.6K | -$135.4K | -$526.5K |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | $69.6K | n/a | n/a |
| Total assets | $347.9K | $274.6K | $483.4K | $658.6K |
| Total liabilities | $12.73M | $6.56M | n/a | $3.25M |
| Shareholders' equity | -$12.39M | -$6.28M | $297.9K | -$2.59M |
| Return on year-end equity | n/a | n/a | -132.1% | n/a |
| Shares outstanding | 8.10M | 39.37M | 406.83M | 108.15M |
Revenue, most recent five fiscal years
| Fiscal year | ZyVersa Therapeutics, Inc. | Regen BioPharma Inc | ProtoKinetix, Inc. | Bioxytran, Inc |
|---|---|---|---|---|
| Latest | n/a | $236.6K Ended 2025-09-30 | $0 Ended 2014-12-31 | $191.1K Ended 2017-12-31 |
| 1 year earlier | n/a | $236.6K Ended 2024-09-30 | $0 Ended 2013-12-31 | $246.5K Ended 2016-12-31 |
| 2 years earlier | n/a | $236.6K Ended 2023-09-30 | $0 Ended 2012-12-31 | $255.8K Ended 2015-12-31 |
| 3 years earlier | n/a | n/a | $0 Ended 2011-12-31 | $275.6K Ended 2014-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2010-12-31 | $417.3K Ended 2013-12-31 |